0.606
-0.16 (-21.26%)
| Previous Close | 0.770 |
| Open | 0.748 |
| Volume | 28,206,464 |
| Avg. Volume (3M) | 3,923,957 |
| Market Cap | 16,265,149 |
| Price / Sales | 0.180 |
| Price / Book | 0.640 |
| 52 Weeks Range | |
| Earnings Date | 28 Jan 2025 |
| Profit Margin | -186.98% |
| Operating Margin (TTM) | -41.87% |
| Diluted EPS (TTM) | -17.51 |
| Quarterly Revenue Growth (YOY) | 34.70% |
| Total Debt/Equity (MRQ) | 96.53% |
| Current Ratio (MRQ) | 1.05 |
| Operating Cash Flow (TTM) | -154.64 M |
| Levered Free Cash Flow (TTM) | -32.56 M |
| Return on Assets (TTM) | -33.18% |
| Return on Equity (TTM) | -193.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | 23andMe Holding Co. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 12.22% |
| % Held by Institutions | 24.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sapphire Ventures, L.L.C. | 31 Dec 2024 | 264,592 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Mar 2025 | Announcement | 23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law |
| 23 Mar 2025 | Announcement | 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process |
| 21 Mar 2025 | Announcement | 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test |
| 03 Mar 2025 | Announcement | 23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki |
| 31 Jan 2025 | Announcement | 23andMe Launches New Genetic Report on Osteoporosis |
| 28 Jan 2025 | Announcement | 23andMe Special Committee Announces Exploration of Strategic Alternatives |
| 28 Jan 2025 | Announcement | 23andMe Reports Third Quarter Fiscal Year 2025 Financial Results |
| 08 Jan 2025 | Announcement | 23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |